Importantly, pharmacological inhibition of USP4 activity enhances KEAP1 ubiquitination, triggering NRF2-dependent antioxidant responses and conferring robust neuroprotection in stroke models—evidenced by reduced neuronal apoptosis and improved functional recovery. Here, USP4 is linked to stroke disorder.